Skymark Research Initiates Independent Research Coverage On Nutra Pharma Corp.

• Press Release
• Source: Skymark Research
• On 8:30 am EDT, Thursday September 10, 2009

CALGARY, Alberta, Sept. 10, 2009 (GLOBE NEWSWIRE) -- Skymark Research, a leading provider of small- and micro-cap independent investment research, today initiated coverage on Nutra Pharma Corp.(OTCBB:NPHC - News). Skymark Research is currently offering a complimentary trial subscription. To view our research go to: www.skymarkresearch.com

Related Quotes

Symbol	Price	Change
NPHC.OB	0.43	+0.01

{"s" : "nphc.ob","k" : "c10,l10,p20,t10","o" : "","j" : ""}

About SMR:

Skymark Research is a leading provider of independent investment research in North America. Our services include research analysis on the small- and micro-cap markets, real-time news and financial data, market commentary and the SMR newsletter. Skymark Research's staff of small-cap investment professionals is dedicated to providing the small market's investment community with the tools and avenues necessary to make the important investment decisions. To view our research reports on a complimentary trial basis and take advantage of our other services, go to www.skymarkresearch.com and click on the complimentary trial subscription button on our home page, or go directly to our registration page at www.skymarkresearch.com/signup.php.

About Nutra Pharma Corp.(OTCBB:NPHC - News):

Nutra Pharma Corp.(OTCBB:NPHC - News) is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

SMR Disclosure:

Skymarkresearch.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. Skymark Research has not been compensated by any of the above mentioned companies. Please read our report and visit our Web site, www.skymarkresearch.com, for complete risks and disclosures.

Skymark Research
Dylan Boyle
202-657-6249
info@skymarkresearch.com